Investment in CGEn

Overview

CGEn is Canada’s national platform for genome sequencing and analysis, with nodes at The Centre for Applied Genomics at The Hospital for Sick Children (SickKids) in Toronto, the McGill Genome Centre in Montreal and Canada’s Michael Smith Genome Sciences Centre at BC Cancer in Vancouver. CGEn is a Major Science Initiative of the Canada Foundation for Innovation (CFI-MSI) providing world-class infrastructure, services, and expertise since being founded in 2015, and enabling novel research and technology development that would otherwise be impossible within Canada. To date CGEn has generated over 12.6 petabases of sequence data for more than 2,900 research labs, companies, and not-for-profits. To remain internationally competitive, CGEn makes considerable efforts in technology development activities to drive forward innovation and formulate new approaches to genomic science. In turn, this ensures that CGEn continues its optimal support of Canada’s research and innovation ecosystem, while remaining in a ready-state to respond to large-scale genomic opportunities and challenges.

This project focuses on technology development driven by demand from the scientific community and aligned with CGEn’s key existing and emerging service growth areas including (i) Long-read sequencing and associated analysis and interpretation of data, (ii) Single cell genomics to produce data on individual cells from a cell population (iii) Spatial transcriptomics to understand intracellular biology with integrated information, ultimately leading to highly accurate tissue specific cell maps, and (iv) Short-read sequencing focusing on the assessment and validation of new technologies. As a result of these technology developments, CGEn will be able to provide important new genomic services to Canadian and international researchers.

Investment in Centre for Biodiversity Genomics

Overview

The Centre for Biodiversity Genomics (CBG) at the University of Guelph holds global leadership in the development and application of species identification systems based on sequence diversity in short, standardized gene regions (DNA barcodes). Termed DNA barcoding, this approach is hugely advancing both our knowledge of the species that share our planet and our capacity to track shifts in their abundance and distribution.

The CBG delivers two key analytical services (informatics, sequencing) to the biodiversity science community; it analyzes millions of specimens and tens of thousands of samples each year by coupling large sequencers with mainframe computers. The award from Genome Canada’s Technology Program will allow the CBG’s Innovation Unit to expand its efforts to develop the laboratory protocols and informatics systems required to capitalize on the capabilities enabled by the thumb-sized DNA sequencers developed by Oxford Nanopore Technologies.

Aside from their speed in delivering data, the low cost of these sequencers and their associated flow cells make them ideal for two purposes – accelerating the development of methods for subsequent implementation in the CBG core facility and making it possible to establish a distributed network of sequencing facilities so nations around the world can track their biodiversity. Because the CBG coordinates the research programs undertaken by the International Barcode of Life Consortium, the advances made by the Innovation Unit in the application of nanopore technology are sure to see rapid uptake on a global scale.

Scispot.io

Overview

Scispot.io Inc (Kitchener) is transforming how genomics research is done with their efficient and integrated data management technology.

What they’re doing: Working on simplifying genomics research with a user-friendly platform that streamlines the collection and analysis of data from tools like DNA sequencers and analysis machines.

How will this be used in the real world? Genetic data is complex, but Scispot’s technology will make it quicker and easier for drug researchers to organize and accurately interpret findings, which can get medications to market faster with over 50% reduced experiment error rate.

AuX Labs

Overview

AuX Labs (Toronto) is creating a vegan version of casein, the natural protein in cow’s milk.

What they’re doing: Through precision fermentation, AuX Labs is developing an affordable vegan casein for the plant-based cheese industry.

How will this be used in the real world? To help meet the demand of the $22-billion vegan food industry, AuxLabs is focused on providing vegan cheese manufacturers with their casein protein to make animal-free cheese that melts, stretches, and tastes just like the animal version.

mDETECT

Overview

mDETECT Inc. (Kingston) is taking precision medicine to the next level with their liquid biopsies for cancer.

What they’re doing: This genomics company has developed highly sensitive blood tests that detect six of the most common cancers (breast, prostate, lung, ovarian, pancreatic and colorectal).

How will this be used in the real world? mDETECT is working on consolidating their tests into a single-tube test that hospitals can use to see how a patient’s cancer is progressing and its response to treatment, simplifying and improving how cancer patient care is managed in Ontario.

Genuine Taste

Overview

Genuine Taste (Toronto) is focused on making cultivated meat taste just like conventional meat.

What they’re doing: Giving cultivated and vegan meat better flavour, aroma and texture with their cultivated beef fat.

How will this be used in the real world? Genuine Taste is increasing production of their cultivated beef fat to help make alternative meat look, taste and smell ‘meatier’. They’re also working with a plant-based meat company to create an ethical, sustainable, and delicious hybrid meat alternative for the food industry.

Virica Biotech

Overview

Virica Biotech (Ottawa) is a medical sciences company using biotechnology to improve the production of cell and gene therapies.

What they’re doing: Using patented innovation, Virica has developed a library of molecules that can be used to combat challenges that naturally occur in the cell therapy production process.

How will this be used in the real world? This ground-breaking approach can help make cell therapies cheaper and easier to produce so more patients can get access to potentially life-saving treatments.

Spectra Plasmonics

Overview

Spectra Plasmonics (Kingston) is perfecting a helpful safety tool for the food and beverage industry.

What they’re doing: Spectra is reworking their successful drug chemical analysis equipment to create biotechnology-based bacteria sensing tests for food producers to assess the quality of their products.

How will this be used in the real world? Commercial kitchens and plants can get on-site, quick and accurate results on the safety of their food before it gets sent out to customers, lessening the chances of food-related illnesses and product recalls.

QurCan Therapeutics

Overview

QurCan Therapeutics (Toronto) is developing technology to boost the effectiveness of cancer-fighting medicines.

What they’re doing: Using genomics innovation, QurCan has created a proprietary nanoparticle drug technology that helps make genetic medicine more affordable and effective with less side effects.

How will this be used in the real world? The new technology allows medicine to target specific parts of the body so it goes exactly where it’s needed, to improve the health outcomes and quality of life for patients.

Escarpment Labs

Overview

Escarpment Labs (Guelph) supplies cutting-edge yeast strains to craft brewers.

What they’re doing: This company of brewers, scientists and fermentation enthusiasts uses genomics technology to create unique liquid brewing yeast and dry yeast for both professional and homebrewers to produce exceptional beverages.

How will this be used in the real world? Escarpment is already supporting the craft beverage industry in Canada, US and Europe with their yeasts that add next level flavour to brews and ensure easier fermentation during the beer making process.